Background: The development of abuse deterrent formulations is one strategy for reducing prescription opioid misuse and abuse. A putative abuse deterrent formulation of oxycodone extended release (OxyContin®) was introduced in 2010. Early reports demonstrated reduced abuse and diversion, however, an analysis of social media found 32 feasible methods to circumventthe abuse deterrent mechanism. We measured trends of diversion, abuse and street price of OxyContin to assess the durability ofthe initial reduction in abuse. Methods: Data from the Poison Center Program, Drug Diversion Program, Opioid Treatment Program, Survey of Key Informant Patients Program and StreetRx program of the Researched Abuse, Diversion, and Addiction-Related Surveillan...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
The rapid and widespread abuse of prescription medications within the United States from the late 19...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
Background: The development of abuse deterrent formulations is one strategy for reducing prescriptio...
AbstractBackgroundThe development of abuse deterrent formulations is one strategy for reducing presc...
IMPORTANCE In an effort to reduce wide-scale abuse of the proprietary oxycodone hydrochloride formul...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Oxycodone hydrochloride controlled-release, also known as extended-release oxycodone (ER oxycodone),...
Background Therapeutic use and abuse of prescription opioids in the United States increased substant...
The introduction of abuse-deterrent OxyContin in 2010 was intended to reduce its misuse by making it...
Background: There is increasing concern about tampering of pharmaceutical opioids. We describe early...
<p><b>Objectives</b>: There is an epidemic of nonmedical and extra-medical use opioid abuse, addicti...
Therapeutic use and abuse of prescription opioids in the United States increased substantially betwe...
AbstractBackgroundDoctor-shopping (obtaining prescriptions from multiple prescribers/pharmacies) for...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
The rapid and widespread abuse of prescription medications within the United States from the late 19...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
Background: The development of abuse deterrent formulations is one strategy for reducing prescriptio...
AbstractBackgroundThe development of abuse deterrent formulations is one strategy for reducing presc...
IMPORTANCE In an effort to reduce wide-scale abuse of the proprietary oxycodone hydrochloride formul...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Oxycodone hydrochloride controlled-release, also known as extended-release oxycodone (ER oxycodone),...
Background Therapeutic use and abuse of prescription opioids in the United States increased substant...
The introduction of abuse-deterrent OxyContin in 2010 was intended to reduce its misuse by making it...
Background: There is increasing concern about tampering of pharmaceutical opioids. We describe early...
<p><b>Objectives</b>: There is an epidemic of nonmedical and extra-medical use opioid abuse, addicti...
Therapeutic use and abuse of prescription opioids in the United States increased substantially betwe...
AbstractBackgroundDoctor-shopping (obtaining prescriptions from multiple prescribers/pharmacies) for...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
The rapid and widespread abuse of prescription medications within the United States from the late 19...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...